These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31756590)

  • 21. [PD-1 blockade therapy in lymphoid malignancies].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
    Hu B; Jacobs R; Ghosh N
    Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
    Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
    Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
    Dada R; Zekri J
    J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
    Lin RJ; Diefenbach CS
    Oncology (Williston Park); 2016 Oct; 30(10):914-20. PubMed ID: 27753058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
    Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
    Liu Y; Huang R; Liu L; Meng Y; Liu X
    Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
    Merryman RW; Armand P; Wright KT; Rodig SJ
    Blood Adv; 2017 Dec; 1(26):2643-2654. PubMed ID: 29296917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
    Allen PB; Gordon LI
    Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1 /PD-L1 checkpoint in hematological malignancies.
    Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
    Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
    Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.